SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

BioNTech, Bristol Myers Report 36.7% Response Rate in NSCLC Trial

BioNTech and Bristol Myers Squibb reported a 36.7% response rate for the pumitamig combination in a Phase II second-line NSCLC trial.

BNTX

Related stories